NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
ESPR Esperion Therapeutics
- 1.770
- +0.190+12.03%
Close Mar 4 16:00 ET
- 1.770
- 0.0000.00%
Post 19:42 ET
346.74MMarket Cap-6.32P/E (TTM)
1.860High1.600Low5.84MVolume1.650Open1.580Pre Close10.28MTurnover2.99%Turnover RatioLossP/E (Static)195.90MShares3.94052wk High-0.89P/B346.14MFloat Cap1.57052wk Low--Dividend TTM195.56MShs Float120.960Historical High--Div YieldTTM16.46%Amplitude0.700Historical Low1.759Avg Price1Lot Size
Esperion Therapeutics Stock Forum
-- FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million --
--Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million --
-- Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q --
-- Focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growt...
Probably gonna close this position too.
25% Canadian tariff exposes ESPR to $12-15M cost increase annually.
Pivot to India for supply, unfortunately Novo Nordisk and other giants did too, resulting in a 14-18M backlog. This will delay their shift to at least 2026, so that's at least 1 year of exposure.
58% Dependence on Medicare funds.
No comment yet